Acurx Pharmaceuticals Inc

NASDAQ:ACXPUnited States

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

Contact Information

Headquarters

259 Liberty AvenueSTATEN ISLAND, NY, United States 10305

Phone

917-533-1469

Fax

302-636-5454

Executives

Executive Chairman, Co-Founder, Managing Partner, Executive Director

Robert Deluccia

President, Chief Executive Officer, Co-Founder, Managing Director

David Luci

Co-Founder, Chief Financial Officer

Robert Shawah

Independent Director

Jack Dean

Independent Director

James Donohue